ProCE Banner Activity

CE / CME

AIMing to Optimize Tardive Dyskinesia Care

Video

On-demand webcast recording of the tardive dyskinesia presentation by Christoph U. Correll, MD, held at the Second Annual Psychiatry Summit.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Social Workers: 1.00 ASWB ACE CE Credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Released: June 13, 2023

Expiration: June 12, 2024

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell,
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine,
Berlin, Germany

Joseph F. Goldberg

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences, Inc. 

Neurocrine Biosciences, Inc.

Target Audience

This educational program is intended for psychiatrists, nurse practitioners, physician associates/physician assistants, general and family practice physicians, gerontologists, pharmacists, psychologists, social workers, and other HCPs who treat patients with tardive dyskinesia who may benefit from this education.

Program Learning Goal

The goal of this program is to provide the latest information spanning a variety of topics about tardive dyskinesia, including screening, diagnosis, and treatment, with considerations for special populations and tardive dyskinesia in long-term care and aging populations.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify relative prevalence and risk of TD across various disease states 

  • Interpret screening tools for the identification of TD, including patient and caregiver reports 

  • Construct an individualized treatment plan for patients with TD with age-related or other special characteristics 

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell,
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine,
Berlin, Germany

Christoph U. Correll, MD, consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Viatris; expert testimony: Janssen, Otsuka; data safety monitoring board: Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Sage, Supernus, Tolmar, Teva; researcher: Janssen, Takeda; stock options: Cardio Diagnostics, Mindpax, LB Pharma, PsiloSterics, Quantic.

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Joseph F. Goldberg, MD: consultant/advisor/speaker: AbbVie, Alkermes, Axsome, BioXcel, Intra-Cellular Therapies, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Gabrielle Giacona and Michael Asbach, DMSc, PA-C, Psych-CAQ, as noted below: 

Gabrielle Giacona: stock/stock options: AstraZeneca, Moderna.

Michael Asbach, DMSc, PA-C, Psych-CAQ: consultant/advisor/speaker: AbbVie, Avanir, Biogen, Janssen, Karuna, Neurocrine, Otsuka.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 13, 2023, through June 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit 

Physician Assistant/Physician Associate Continuing Medical Education 
Joint Accreditation

 

Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 12, 2024. PAs should only claim commensurate with the extent of their participation.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number -  JA4008176-0000-23-163-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Psychologist Continuing Education


Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer 1 continuing education credit for psychologists.

Social Work Continuing Education


As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 clinical continuing education credit.